Johns Hopkins scientists report that adult cells reprogrammed to become primitive stem cells, called induced pluripotent stem cells (iPSCs), make tiny “cargo packets” able to deliver potentially restorative or repairing proteins, antibodies or other therapies to aged cells. Because They say the human iPSCs they studied produced much more of the packets, formally known as extracellular vesicles; than other kinds of adult stem cells commonly used for this purpose in research.
Induced pluripotent stem
Extracellular vesicles are naturally abundant in many types of cells, which use the cargo-containing spheres to communicate with other cells. They are about one one-hundredth the diameter of a cell and can carry anything from fats and proteins to nucleic acids. When a cell releases an extracellular vesicle; other cells nearby slurp up the tiny packet and its contents; making it an attractive target for packaging treatments for diseased cells that are deteriorating or aging prematurely; researchers say.
To package a potential treatment in an extracellular vesicle, therefore scientists typically use a cell called a mesenchymal stem cell, which is found among fat or bone marrow cells and gives rise to other fat and bone cells. Scientists genetically modify the stem cell to produce vesicles with the treatment-related cellular therapy usually a protein.
The Extracellular vesicles
But the Johns Hopkins scientists say that mesenchymal stem cells aren’t the best sources for extracellular vesicles. The cells don’t multiply as often as iPSCs, and more cells are necessary to produce larger quantities of extracellular vesicles needed for therapeutic use.
In addition, mesenchymal cells grow best in a liquid called fetal bovine serum; because which contains potentially treatment-contaminating extracellular vesicles that are difficult to distinguish and separate from extracellular vesicles derived from mesenchymal cells.
Medicine and oncology
By contrast, the liquid used to store and feed human iPSCs in the laboratory; called Essential 8; is free of extracellular vesicles and animal proteins; and the Johns Hopkins scientists found the cells could produce 16 times more vesicles than mesenchymal stem cells.
“We wanted to show other scientists working on such potential therapies that human iPSCs can efficiently produce highly purified extracellular vesicles that could; therefore one day, be use to treat aging-related diseases;” says Linzhao Cheng, Ph.D., a professor of medicine and oncology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center.
Cheng and his colleague Vasiliki Machairaki, Ph.D., assistant professor of neurology at the Johns Hopkins University School of Medicine; postdoctoral fellow Senquan Liu and other colleagues reported results of their experiments online Feb. 27 in Stem Cells.